XML 44 R28.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Schedule of Segment Information | (in thousands):
|  | Three Months Ended March 31,
|  | 2023 |  | 2022
Net revenues: |  |  |  |
Clinical Services |  | $ | 114,869 |  |  | $ | 98,791 |
Pharma Services |  | 22,351 |  |  | 18,378 |
Total revenue |  | 137,220 |  |  | 117,169 |
Cost of revenue: |  |  |  |
Clinical Services(1) |  | 67,292 |  |  | 65,267 |
Pharma Services(2) |  | 15,114 |  |  | 13,670 |
Total cost of revenue |  | 82,406 |  |  | 78,937 |
Gross Profit: |  |  |  |
Clinical Services |  | 47,577 |  |  | 33,524 |
Pharma Services |  | 7,237 |  |  | 4,708 |
Total gross profit |  | 54,814 |  |  | 38,232 |
Operating expenses: |  |  |  |
General and administrative |  | 61,549 |  |  | 66,248 |
Research and development |  | 7,395 |  |  | 7,713 |
Sales and marketing |  | 16,259 |  |  | 16,299 |
Restructuring charges |  | 4,684 |  |  | — |
Total operating expenses |  | 89,887 |  |  | 90,260 |
Loss from operations |  | (35,073) |  |  | (52,028) |
Interest (income) expense, net |  | (1,467) |  |  | 1,301 |
Other (income) expense, net |  | 114 |  |  | (168) |
Loss before taxes |  | (33,720) |  |  | (53,161) |
Income tax benefit |  | (2,925) |  |  | (3,753) |
Net loss |  | $ | (30,795) |  |  | $ | (49,408) |
(1) Clinical Services cost of revenue for both the three months ended March 31, 2023 and 2022 includes $4.3 million of amortization of acquired Inivata developed technology intangible assets. (2) Pharma Services cost of revenue for both the three months ended March 31, 2023 and 2022 include $0.6 million of amortization of acquired Inivata developed technology intangible assets.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration